Anne M. Phillips

Anne Phillips, MD has served as an Independent Director at Carmot since 2022. Prior to joining Carmot, Dr Phillips was Senior Vice President, Clinical Development, Medical & Regulatory Affairs for Novo Nordisk Inc. since March 2013. At Novo, she led an integrated team across drug development, clinical operations, medical, regulatory, health economics and outcomes research, and pharmacovigilance. Dr. Phillips played a key role in advancing Novo Nordisk’s diabetes, obesity and biopharmaceuticals clinical development pipelines and was responsible for the efficient development and delivery of compounds in clinical trials, including product lifecycle and in-licensed compounds.

Before joining Novo Nordisk in 2011, Dr. Phillips was Vice President of Clinical Development at GlaxoSmithKline (GSK), leading diverse global and regional clinical teams supporting cardiovascular, metabolic, and oncology medicines, as well as drug discovery and Biotech alliance creation and execution. While at GSK, she provided clinical leadership and partnership in the management of one of the company’s largest medicines and formulated a deep level of understanding of the needs of both patients and healthcare professionals.

Dr. Phillips has worked in the Pharmaceutical Industry on programs in cardiovascular, metabolic, oncology/hematology, and in roles including drug discovery, business development, safety and pharmaco-vigilence and as leader of Clinical Development, Medical and Regulatory Affairs (CMR) as well as Head of R&D.

Previously, Dr Phillips was Head of the Infectious Diseases Program and Deputy Physician-in-Chief at Wellesley Central Hospital/St. Michael’s Hospital in Toronto and is a Fellow of The Royal College of Physicians and Surgeons of Canada.